Evidence map›Paper›PMID 33579769›Full record

ArticleBMJ open2021

Seroprevalence of antibodies to SARS-CoV-2 in healthcare workers: a cross-sectional study.

Joseph E Ebinger, Gregory J Botwin, Christine M Albert, Mona Alotaibi, Moshe Arditi, Anders H Berg, Aleksandra Binek, Patrick Botting, Justyna Fert-Bober, Jane C Figueiredo and 29 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

39 authors.

Joseph E EbingerDepartment of Cardiology, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Gregory J BotwinF. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Christine M AlbertDepartment of Cardiology, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Mona AlotaibiDivision of Pulmonary and Critical Care Medicine, University of California, San Diego, La Jolla, California, USA.
Moshe ArditiSmidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Anders H BergDepartment of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Aleksandra BinekAdvanced Clinical Biosystems Institute, Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Patrick BottingDepartment of Cardiology, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Justyna Fert-BoberSmidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Jane C FigueiredoCedars-Sinai Cancer and Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Jonathan D GreinDepartment of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Wohaib HasanDepartment of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Mir HenglinDepartment of Cardiology, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Shehnaz K HussainDepartment of Public Health Sciences and Comprehensive Cancer Center, University of California, Davis, Davis, California, USA.
Mohit JainDepartment of Medicine and Pharmacology, University of California, San Diego, La Jolla, California, USA.
Sandy JoungDepartment of Cardiology, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Michael KarinDepartment of Pharmacology, University of California San Diego School of Medicine, La Jolla, California, USA.
Elizabeth H KimDepartment of Cardiology, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Dalin LiF. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Yunxian LiuDepartment of Cardiology, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Eric LuongDepartment of Cardiology, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Dermot P B McGovernF. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Akil MerchantDepartment of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Noah MerinDepartment of Internal Medicine, Division of Hematology, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Peggy B MilesEmployee Health Services, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Margo MinissianDepartment of Cardiology, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Trevor Trung NguyenDepartment of Cardiology, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Koen RaedscheldersDepartment of Cardiology, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Mohamad A RashidDepartment of Cardiology, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Celine E RieraCenter for Neural Science and Medicine, Department of Biomedical Sciences, Board of Governors Regenerative Medicine Institute, Department of Neurology, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Richard V RiggsChief Medical Officer, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Sonia SharmaLa Jolla Institute for Allergy and Immunology, La Jolla, California, USA.
Sarah SternbachSmidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Nancy SunDepartment of Cardiology, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Warren G TourtellotteDepartment of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Jennifer E Van EykDepartment of Cardiology, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Kimia SobhaniDepartment of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA susan.cheng@cshs.org Jonathan.Braun2@cshs.org Kimia.Sobhani@cshs.org.
Jonathan G BraunDepartment of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA susan.cheng@cshs.org Jonathan.Braun2@cshs.org Kimia.Sobhani@cshs.org.
Susan ChengDepartment of Cardiology, Cedars-Sinai Medical Center, Los Angeles, California, USA susan.cheng@cshs.org Jonathan.Braun2@cshs.org Kimia.Sobhani@cshs.org.ORCID 0000-0002-4977-036X

Funding

Diversity and Determinants of the Immune-Inflammatory Response to SARS-CoV-2U54CA260591 · NCI · CEDARS-SINAI MEDICAL CENTER · PI FIGUEIREDO, JANE C., KARIN, MICHAEL · 2020 to 2024
$9.1M
Implementation Science to Improve Cardiovascular Health: Leveraging EHR Systems to Advance Care of Resistant HypertensionK23HL153888 · NHLBI · CEDARS-SINAI MEDICAL CENTER · PI EBINGER, JOSEPH · 2020 to 2024
$929k
NCI NIH HHS U54 CA260591NHLBI NIH HHS K23 HL153888
6 · The paper itself

Abstract

objectiveWe sought to determine the extent of SARS-CoV-2 seroprevalence and the factors associated with seroprevalence across a diverse cohort of healthcare workers.

designObservational cohort study of healthcare workers, including SARS-CoV-2 serology testing and participant questionnaires. SETTINGS: A multisite healthcare delivery system located in Los Angeles County.

participantsA diverse and unselected population of adults (n=6062) employed in a multisite healthcare delivery system located in Los Angeles County, including individuals with direct patient contact and others with non-patient-oriented work functions. MAIN OUTCOMES: Using Bayesian and multivariate analyses, we estimated seroprevalence and factors associated with seropositivity and antibody levels, including pre-existing demographic and clinical characteristics; potential COVID-19 illness-related exposures; and symptoms consistent with COVID-19 infection.

resultsWe observed a seroprevalence rate of 4.1%, with anosmia as the most prominently associated self-reported symptom (OR 11.04, p<0.001) in addition to fever (OR 2.02, p=0.002) and myalgias (OR 1.65, p=0.035). After adjusting for potential confounders, seroprevalence was also associated with Hispanic ethnicity (OR 1.98, p=0.001) and African-American race (OR 2.02, p=0.027) as well as contact with a COVID-19-diagnosed individual in the household (OR 5.73, p<0.001) or clinical work setting (OR 1.76, p=0.002). Importantly, African-American race and Hispanic ethnicity were associated with antibody positivity even after adjusting for personal COVID-19 diagnosis status, suggesting the contribution of unmeasured structural or societal factors. CONCLUSION AND RELEVANCE: The demographic factors associated with SARS-CoV-2 seroprevalence among our healthcare workers underscore the importance of exposure sources beyond the workplace. The size and diversity of our study population, combined with robust survey and modelling techniques, provide a vibrant picture of the demographic factors, exposures and symptoms that can identify individuals with susceptibility as well as potential to mount an immune response to COVID-19.

Indexed as

Health PersonnelSeroepidemiologic StudiesAdultAntibodies, ViralBayes TheoremCohort StudiesCOVID-19COVID-19 Serological TestingCross-Sectional StudiesFemaleHumansLos AngelesMaleMiddle AgedSARS-CoV-2Antibodies, ViralCOVID-19infectious diseasespublic health

Identifiers

PMID33579769
PMCPMC7883610

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.